Clinical trials · Texas
Locally Advanced (Unresectable) or Metastatic Solid Tumors clinical trials in Texas
We’re tracking 528 recruiting locally advanced (unresectable) or metastatic solid tumors studies with a site in Texas — including Phase 1, Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in Texas
- NCT07174583RecruitingPhase 1/Phase 2
Study of IDE849 for DLL3-positive cancers like SCLC
This trial tests a new drug called IDE849 for cancers that make a protein called DLL3, including small cell lung cancer and some neuroendocrine tumors. It is for people whose cancer has progressed after standard treatments, and may be given alone or combined with other drugs like durvalumab or IDE161.
Houston, TexasAges 18 years+ - NCT07139990RecruitingPhase 1
Personalized radiotherapy for lung, brain, sarcoma, or head and neck cancers
This trial tests whether giving personalized radiotherapy alongside standard treatments can better control several types of cancer: small cell lung cancer, brain metastases, soft tissue sarcoma, and head and neck cancer. It aims to see if this approach helps patients live longer without their cancer growing or coming back.
Dallas, TexasAges 18 years+ - NCT07043400RecruitingPhase 3
Study comparing two ways to give tislelizumab plus chemo for stomach cancer
This trial compares a shot under the skin versus an IV infusion of tislelizumab, given along with chemotherapy, for people with advanced stomach or gastroesophageal junction cancer that has not been treated before. The goal is to see if the shot works as well as the IV and may be more convenient.
Houston, TexasAges 18 years+ - NCT07011719RecruitingPhase 3
Kidney cancer trial: new combo vs. cabozantinib alone
This trial tests a new drug (casdatifan) combined with cabozantinib for advanced clear cell kidney cancer, comparing it to cabozantinib alone. It's for people who haven't taken these specific medicines before and are still in fairly good health.
Lubbock, TexasAges 18 years+ - NCT06772623RecruitingPhase 1/Phase 2
Study of telisotuzumab adizutecan plus immunotherapy for advanced lung cancer
This trial tests a new combination treatment for people with advanced non-squamous non-small cell lung cancer who haven't received prior therapy for advanced disease and don't have specific gene changes. The treatment includes an antibody-drug conjugate (telisotuzumab adizutecan) plus an immunotherapy drug (PD-1 checkpoint inhibitor) to see if it helps shrink tumors and improve outcomes.
Houston, TexasAges 18 years+ - NCT06725758RecruitingPhase 1/Phase 2
First-in-human study of ODM-212 for advanced solid tumors
This study tests an experimental drug called ODM-212 for people with advanced solid tumors that have not responded to standard treatments. It may be especially relevant if your tumor has changes in the Hippo pathway (certain genes like NF2 or YAP/TAZ).
Houston, TexasAges 18 years+ - NCT06474676RecruitingPhase 1
Modified immune cell therapy for advanced sarcoma
This trial tests a new treatment using your own immune cells (TILs) that have been modified to attack sarcoma tumors. It is for people with advanced soft tissue or bone sarcoma who have already tried at least one other therapy.
Houston, TexasAges 12 years+ - NCT06369259RecruitingPhase 2
Combination treatment for advanced colorectal cancer that resisted standard therapy
This clinical trial tests a new combination of three drugs for people with advanced colorectal cancer that has not responded to standard anti-EGFR treatments. The goal is to see if this combination can shrink tumors or slow the cancer down.
Houston, TexasAges 18 years+ - NCT06343402RecruitingPhase 1
Study of BBO-8520 for advanced KRAS G12C lung cancer
This trial tests a new oral medication called BBO-8520 for advanced lung cancer with a specific gene change (KRAS G12C mutation). It aims to see if the drug is safe and effective, and may be combined with another drug (pembrolizumab) in some groups.
Houston, TexasAges 18 years+ - NCT06118086RecruitingPhase 1/Phase 2
Study of REM-422 for advanced adenoid cystic carcinoma
This trial tests an experimental drug called REM-422 for people with adenoid cystic carcinoma (ACC) that has spread, come back, or cannot be removed by surgery. The study has two parts: an early part for people with advanced ACC and a later part for those with a specific genetic change (MYB biomarker) in their tumor. The goal is to see if REM-422 can slow or stop cancer growth.
Houston, TexasAges 18 years+ - NCT05985954RecruitingPhase 1
Ulixertinib with cetuximab for colorectal cancer
This trial tests whether the drug ulixertinib, combined with cetuximab (and sometimes encorafenib), can help people with advanced or metastatic colorectal cancer who have already tried EGFR or BRAF-targeted therapy. It aims to find new treatment options for these patients.
Houston, TexasAges 18 years+ - NCT05967689RecruitingPhase 2
Zipalertinib for lung cancer with EGFR exon 20 mutations
This Phase 2 trial tests zipalertinib (a targeted pill) in people with advanced non-small cell lung cancer (NSCLC) that has specific EGFR mutations, especially “exon 20 insertions.” It may help shrink tumors or slow cancer growth, including in some people with brain metastases.
Houston, TexasAges 18 years+ - NCT04300556RecruitingPhase 1/Phase 2
Testing an antibody-drug for advanced certain cancers
This early-phase trial tests a treatment called MORAb-202, an antibody “delivery” drug, to see if it’s safe and can help shrink or control certain advanced cancers. It may help people whose tumors match the study’s specific cancer types and prior treatment history.
Houston, TexasAges 18 years+ - NCT07700979RecruitingPhase 3
Testing a new drug combo for stomach cancer
This trial tests a new immunotherapy drug called cadonilimab combined with chemotherapy for people with advanced stomach cancer that hasn't been treated yet. It compares this combination to chemotherapy with or without another immunotherapy drug, nivolumab.
Dallas, TexasAges 18 years+ - NCT07621614RecruitingPhase 2
Safe Surgery Guidance for Childhood Melanoma Using Genetics
This study helps doctors decide the safest surgical approach for melanoma and similar skin tumors in children and young adults by using pathology reports and genetic information. The goal is to avoid unnecessary surgery while ensuring the best outcomes.
Austin, TexasAges Up to 25 years - NCT05668962RecruitingPhase 2
Study selpercatinib plus I-131 for RET thyroid cancer that cannot take iodine
This trial tests whether combining a targeted pill (selpercatinib) with a radioactive iodine dose (I-131) can shrink thyroid cancer that has spread and no longer responds to radioactive iodine. It is for RET fusion–positive (genetically driven) thyroid cancers where the cancer cannot reliably absorb iodine anymore.
Houston, TexasAges 12 years+ - NCT07535112RecruitingPhase 1
Study of a new drug for advanced colorectal cancer with KRAS G12D mutation
This trial tests an experimental drug (BAY 3771249) for people with advanced or metastatic colorectal cancer that has a specific genetic change called KRAS G12D. The goal is to see if the drug is safe and if it can help shrink tumors.
Irving, TexasAges 18 years+ - NCT07525141RecruitingPhase 1
Testing JNJ-1761981 for advanced solid tumors
This early-stage trial tests a new drug called JNJ-1761981 in people with solid tumors (cancers that form in organs or tissues, excluding brain tumors) that have spread or returned after standard treatment. The study aims to find the right dose and see how well the drug works.
Houston, TexasAges 18 years+ - NCT07431281RecruitingPhase 3
New drug combo for advanced stomach cancer with CLDN18.2
This trial tests a new drug combination for people with advanced stomach cancer that has not been treated before. It looks at two groups: one with PD-L1 (a protein that helps decide if immunotherapy works), and one without. The treatment includes an antibody-drug conjugate (Sonesitatug Vedotin) plus standard chemotherapy, with or without an immunotherapy drug.
Sherman, TexasAges 18 years+ - NCT07247110RecruitingPhase 1
Study of MK-4716 for people with certain solid tumors
This trial tests a new drug, MK-4716, alone or with cetuximab or pembrolizumab, for people with advanced solid tumors that have a specific KRAS gene change. It aims to see if the drug can shrink tumors or slow their growth.
Irving, TexasAges 18 years+ - NCT07227350RecruitingPhase 2
L19IL2 and L19TNF for advanced basal cell carcinoma
This trial tests a combination of two drugs, L19IL2 and L19TNF, injected directly into advanced basal cell carcinoma tumors that cannot be treated with surgery or radiation. The goal is to see if these drugs can shrink the tumors.
Houston, TexasAges 18 years+ - NCT07213791RecruitingPhase 1
Study of a new drug for FAP-positive cancers
This trial tests a new drug (LY4337713) for cancers that have a specific protein called FAP on their surface. It may be an option for people whose cancer has continued to grow after standard treatments.
Dallas, TexasAges 18 years+ - NCT07192432RecruitingPhase 1/Phase 2
Gene therapy for HER2-positive cancer
This trial tests a new gene therapy for people with HER2-positive cancer. It is for two groups: those with advanced cancer that has worsened after treatment, and those with early-stage cancer at high risk of coming back. The goal is to see if the therapy can safely help shrink tumors or prevent return.
Houston, TexasAges 18 years+ - NCT07162480RecruitingPhase 2
Investigational Drug for Advanced Salivary Gland Cancer (Adenoid Cystic Carcinoma)
This clinical trial studies an experimental drug called AZD8205 for people with a specific type of advanced adenoid cystic carcinoma (ACC). ACC is a rare cancer that usually starts in the salivary glands. The trial aims to see if the drug can shrink tumors or slow the disease, and it's for those whose cancer has spread or come back and fits certain molecular features.
Houston, TexasAges 18 years+
Locally Advanced (Unresectable) or Metastatic Solid Tumors trials by city in Texas
Where these studies are running in Texas
Institutions with a site for the recruiting locally advanced (unresectable) or metastatic solid tumors studies listed above.
- The University of Texas MD Anderson Cancer Center · 16 studies
- Research Site · 2 studies
- Baylor College of Medicine
- Baylor Scott & White Health
- Baylor Scott and White Medical Center Temple
- Dell Children's Medical Center of Central Texas
- Joe Arrington Cancer Research & Treatment Center
- Millennium Physicians
What taking part in a locally advanced (unresectable) or metastatic solid tumors study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Common questions
- Are there locally advanced (unresectable) or metastatic solid tumors clinical trials in Texas?
- Yes. We're currently tracking 528 recruiting locally advanced (unresectable) or metastatic solid tumors studies with a site in Texas, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a locally advanced (unresectable) or metastatic solid tumors study in Texas?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Texas to take part?
- Not necessarily. These studies have a site in Texas, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a locally advanced (unresectable) or metastatic solid tumors trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New locally advanced (unresectable) or metastatic solid tumors studies open in Texas regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.